Company Filing History:
Years Active: 2014
Title: Amy Xiang: Innovator in Glucokinase Modulation
Introduction
Amy Xiang is a prominent inventor based in Bridgewater, NJ (US). She has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate glucokinase activity. With a total of 2 patents to her name, her work is paving the way for new treatments for metabolic disorders.
Latest Patents
Amy's latest patents include innovative compounds aimed at treating glucokinase-mediated disorders. The first patent, titled "Substituted dihydroisoindolones as allosteric modulators of glucokinase," focuses on compounds that can effectively modulate glucokinase, which is crucial for managing type II diabetes. The second patent, "Substituted pyrrolones as allosteric modulators of glucokinase," also targets glucokinase modulation, providing further options for treating similar disorders.
Career Highlights
Amy Xiang is currently employed at Janssen Pharmaceutica NV, where she continues to advance her research in glucokinase modulation. Her work is instrumental in developing new therapeutic strategies for diabetes and other related conditions.
Collaborations
Amy collaborates with talented colleagues, including Maud J Urbanski and Roxanne Zeck, who contribute to her innovative research efforts.
Conclusion
Amy Xiang's contributions to glucokinase modulation represent a significant advancement in the treatment of metabolic disorders. Her innovative patents and collaborative efforts highlight her role as a leading inventor in the pharmaceutical industry.